🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

WHO warns individuals against mixing and matching COVID vaccines

Published 07/12/2021, 11:51 AM
Updated 07/13/2021, 09:31 PM
© Reuters. FILE PHOTO: World Health Organization (WHO) Chief Scientist Soumya Swaminathan attends a press conference organised by the Geneva Association of United Nations Correspondents (ACANU) amid the COVID-19 outbreak, caused by the novel coronavirus, at the WHO
PFE
-
AZN
-
MRNA
-

(This story corrects spelling of Novavax (NASDAQ:NVAX) in last paragraph)

GENEVA (Reuters) - The World Health Organization's chief scientist has advised individuals against mixing and matching COVID-19 vaccines from different manufacturers, saying such decisions should be left to public health authorities.

"It's a little bit of a dangerous trend here," Soumya Swaminathan told an online briefing on Monday after a question about booster shots. "It will be a chaotic situation in countries if citizens start deciding when and who will be taking a second, a third and a fourth dose."

Swaminathan had called mixing a "data-free zone" but later clarified her remarks in an overnight tweet.

"Individuals should not decide for themselves, public health agencies can, based on available data," she said in the tweet. "Data from mix and match studies of different vaccines are awaited - immunogenicity and safety both need to be evaluated."

© Reuters. FILE PHOTO: World Health Organization (WHO) Chief Scientist Soumya Swaminathan attends a press conference organised by the Geneva Association of United Nations Correspondents (ACANU) amid the COVID-19 outbreak, caused by the novel coronavirus, at the WHO headquarters in Geneva Switzerland July 3, 2020. Fabrice Coffrini/Pool via REUTERS

The WHO's Strategic Advisory Group of Experts on vaccines said in June the Pfizer Inc (NYSE:PFE) vaccine could be used as a second dose after an initial dose of AstraZeneca (NASDAQ:AZN), if the latter is not available.

A clinical trial led by the University of Oxford in the UK is ongoing to investigate mixing the regimen of AstraZeneca and Pfizer vaccines. The trial was recently expanded to include the Moderna (NASDAQ:MRNA) Inc and Novavax Inc vaccines.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.